Key Figures Q4/Full Year 2019

SEK m, unless otherwise stated

2019

Oct-Dec

2018

Oct-Dec

2019

Jan-Dec

2018

Jan-Dec

Δ

2018-2019

Net revenues

238.1

227.1

844.8

783.1

8%

whereof Zubsolv® US net revenues

190.5

166.7

719.2

621.5

16%

Cost of goods sold

-23.0

-43.4

-105.6

-171.8

-39%

Operating expenses

-143.5

-146.1

-508.0 

-515.6

-1%

EBIT

71.5

37.6

231.2

95.8

141%

EBIT margin, %

30.0

16.6

27.4

12.2

15.2 ppt

US EBIT

98.2

62.0

350.9

198.3

77%

US EBIT margin, %

51.6

37.2

48.8

31.9

16.9 ppt

EBITDA

85.8

42.8

272.1

116.6

133%

Earnings per share, before dilution, SEK

1.12

1.49

6.33

3.99

59%

Earnings per share, after dilution, SEK

1.10

1.47

6.20

3.93

58%

Cash flow from operating activities

60.2

71.7

290.9

242.0

20%

Cash and cash equivalents

816.8

589.8

816.8

589.8

38%

 

Distribution of Net Revenues Q4/Full Year 2019

SEK m

2019

Oct-Dec

2018

Oct-Dec

2019

Jan-Dec

2018

Jan-Dec

Zubsolv® US

190.5

166.7

719.2

621.5

Zubsolv - ex US

0.0

5.2

0.1

36.2

Zubsolv – total

190.5

171.9

719.3

657.8

Abstral® royalties

46,2

52.4

112.6

118.8

Edluar® royalties

1.3

2.9

11.6

6.6

OX-MPI

0.0

-

1.4

-

Total

238.1

227.1

844.8

783.1

Cash flow Q4/Full Year 2019

SEK m

2019

Oct-Dec

2018

Oct-Dec

2019

Jan-Dec

2018

Jan-Dec

Cash flow from operating activities

60.2

71.7

290.9

242.0

Investment activities

-11.0

-3.9

-26.3

-6.2

Financing activities

-4.3

0.0

-53.7

0.0

Cash flow (excl exchange rate differences)

44.8

67.8

210.8

235.8

Liquid funds

816.8

589.8

816.8

589.8